🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

WHO ramps up HIV drug push with call for early treatment for all

Published 09/30/2015, 04:54 AM
Updated 09/30/2015, 04:59 AM
© Reuters. Ruth Munyao, a pharmacist, dispenses anti-retroviral (ARV) drugs at the Mater Hospital in Kenya's capital Nairobi
GILD
-
GSK
-

By Stephanie Nebehay

GENEVA (Reuters) - Everyone with HIV should be given anti-retroviral drugs as soon as possible after diagnosis, meaning 37 million people worldwide should be on treatment, the World Health Organization (WHO) said on Wednesday.

Recent clinical trials have confirmed that early drug use extends the lives of those with the AIDS-causing virus and cuts the risk of disease transmission to partners, the WHO said in a statement setting out the new goal for its 194 member states.

Under previous WHO guidelines, which limited treatment to those whose immune cell counts had fallen below a certain threshold, 28 million people were deemed eligible for anti-retroviral therapy (ART).

All people at "substantial" risk of contracting HIV should also be given preventive ART, not just men who have sex with men, the WHO said.

The new guidelines are a central plank of the United Nations agency's aim to end the AIDS epidemic by 2030.

"Everybody living with HIV has the right to life-saving treatment. The new guidelines are a very important step towards ensuring that all people living with HIV have immediate access to anti-retroviral treatment," said Michel Sidibe, executive director of UNAIDS.

"According to UNAIDS estimates, expanding ART to all people living with HIV and expanding prevention choices can help avert 21 million AIDS-related deaths and 28 million new infections by 2030."

The move will lead to a sharp increase in demand for ART medicines, which are typically given as a three-drug cocktail to avoid the risk of the virus developing resistance.

Major suppliers of HIV drugs include Gilead Sciences (O:GILD), ViiV Healthcare, which is majority-owned by GlaxoSmithKline (L:GSK), and multiple Indian generic manufacturers.

The medical charity Medecins Sans Frontieres (Doctors Without Borders) welcomed the WHO's "treat-all" plan, which it believes will prevent many HIV-positive people in poorer countries from falling through the treatment net.

MSF said its experience showed that a third of people who were diagnosed with HIV, but not eligible to start treatment, never returned to the clinic.

The charity also warned that making the new recommendation a reality would require dramatically increased financial support from donors and governments.

The WHO estimates that by 2020 low- and lower-middle income countries will need $18.4 billion annually for the expanded HIV fight. However, fast-tracking the response should yield economic returns of $15 per dollar invested, based on improved health and infections averted.

© Reuters. Ruth Munyao, a pharmacist, dispenses anti-retroviral (ARV) drugs at the Mater Hospital in Kenya's capital Nairobi

Since it began spreading 30 years ago, AIDS has killed around 40 million people worldwide.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.